Genomic sequencing specialist GenapSys picked up $37 million in Series B financing to help develop and commercialize its diagnostic system for genetic diseases, cancer and microbes. The California company's GENIUS 110--Gene Electronic Nano-Integrated Ultra-Sensitive--is designed to be inexpensive and easy to use, according to the company, combining advanced fluidics and analytics for DNA and RNA sequencing. The cash infusion follows a recent trend of sizable investments in next-gen sequencing, including $15 million for NextCODE Health and $50 million for Enzymatics, both Massachusetts outfits. "I believe now is the decade of genomics," GenapSys CEO Hesaam Esfandyarpour said in a statement. More from FierceDiagnostics